Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases.
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
12
2018
revised:
21
01
2019
accepted:
05
02
2019
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly present with metastatic disease, and the liver is the most frequent metastatic site. Herein, we studied whether primary tumor site affects survival in patients with GEP-NETs and liver metastases (NELM). As a secondary endpoint, we studied whether extrahepatic disease and surgical resection impact survival in this patient population. Patients with NELM diagnosed from 2006 to 2014 were identified from the National Cancer Database. Kaplan-Meier curves and nested Cox proportional hazards were used to assess variables associated with survival. 2947 patients with well- or moderately differentiated GEP-NETs and NELM met the inclusion criteria for this study. Patients with small bowel NETs survived the longest of all GEP-NETs with NELM (median not reached). Rectal and gastric NETs with NELM had the shortest survival (median 31 months). Patients with extrahepatic metastases who underwent any operation survived longer than those managed nonoperatively (median survival 38.7 months vs. 18.6 months, Primary tumor site affects survival in patients with GEP-NETs and NELM. Surgical resection seems beneficial for all GEP-NETs with NELM, even in the presence of extrahepatic metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly present with metastatic disease, and the liver is the most frequent metastatic site. Herein, we studied whether primary tumor site affects survival in patients with GEP-NETs and liver metastases (NELM). As a secondary endpoint, we studied whether extrahepatic disease and surgical resection impact survival in this patient population.
METHODS
METHODS
Patients with NELM diagnosed from 2006 to 2014 were identified from the National Cancer Database. Kaplan-Meier curves and nested Cox proportional hazards were used to assess variables associated with survival.
RESULTS
RESULTS
2947 patients with well- or moderately differentiated GEP-NETs and NELM met the inclusion criteria for this study. Patients with small bowel NETs survived the longest of all GEP-NETs with NELM (median not reached). Rectal and gastric NETs with NELM had the shortest survival (median 31 months). Patients with extrahepatic metastases who underwent any operation survived longer than those managed nonoperatively (median survival 38.7 months vs. 18.6 months,
CONCLUSIONS
CONCLUSIONS
Primary tumor site affects survival in patients with GEP-NETs and NELM. Surgical resection seems beneficial for all GEP-NETs with NELM, even in the presence of extrahepatic metastases.
Identifiants
pubmed: 30992703
doi: 10.1155/2019/9871319
pmc: PMC6434277
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9871319Références
J Am Coll Surg. 2003 Jul;197(1):29-37
pubmed: 12831921
Surgery. 1990 Dec;108(6):1091-6
pubmed: 1701060
Surgery. 2006 Dec;140(6):891-7; discussion 897-8
pubmed: 17188135
Surgery. 2007 Jul;142(1):10-9
pubmed: 17629995
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Am J Surg. 2012 May;203(5):628-631
pubmed: 22459446
Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):306-13
pubmed: 22760514
Surgery. 2012 Dec;152(6):998-1007
pubmed: 23158174
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Clin Exp Metastasis. 2014 Dec;31(8):935-44
pubmed: 25241033
Surgery. 2014 Dec;156(6):1369-76; discussion 1376-7
pubmed: 25456912
Surgery. 2016 Jan;159(1):320-33
pubmed: 26454679
Surg Oncol Clin N Am. 2016 Jan;25(1):217-25
pubmed: 26610783
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Ann Surg. 2017 Aug;266(2):333-338
pubmed: 27429020
Ann Surg. 2017 Jan;265(1):158-165
pubmed: 28009741
J Surg Oncol. 2017 May;115(6):687-695
pubmed: 28146608
Ann Surg Oncol. 2017 Aug;24(8):2319-2325
pubmed: 28303430
J Surg Oncol. 2017 Dec;116(7):841-847
pubmed: 28650564
J Gastrointest Surg. 2017 Dec;21(12):2039-2047
pubmed: 28744737
Pancreas. 2018 Mar;47(3):321-325
pubmed: 29401168
JAMA Surg. 2018 Sep 1;153(9):850-851
pubmed: 29617542
Surgery. 2019 Jan;165(1):178-185
pubmed: 30415869